Swedish biopharmaceutical company Sobi (STO:SOBI) on Wednesday reported topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN gamma)-driven sepsis (IDS).
The company says that the study showed proof-of-concept with observed improvement in organ dysfunction and survival. Based on the observed data from this research collaboration with the Hellenic Institute for the Study of Sepsis (HISS), Sobi and HISS will advance emapalumab in IDS and discuss the next clinical development steps with regulatory authorities.
Data from the EMBRACE study will be published at an upcoming medical conference.
The Phase 2a, double-blind, randomised controlled trial was conducted at 24 sites in Greece. HISS sponsored the study as part of a research collaboration with Sobi.
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Health Canada approves AbbVie's eight-week MAVIRET regimen for acute and chronic hepatitis C
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens
Nimbus Therapeutics partners with Lilly to develop oral obesity treatment
BioArctic and Eisai secure Chinese acceptance for subcutaneous Leqembi filing
Oculis secures FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis
Nanjing Delova Biotech reports positive Phase 3 trial results for QP-6211 for postoperative pain
MetaVia reports positive results from Phase 1 clinical trial in obesity
RedHill advances RHB-102 across GI indications
Halozyme licenses ENHANZE to Skye Bioscience for nimacimab obesity programme
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China